Our western-blot analysis revealed that CFM-4.16, but not CFM-4 or Everolimus, robustly inhibited expression as well as activation/phosphorylation of Akt in Everolimus-resistant A498 RCC cells (Figure 3D). Here, AKT1 is linked to renal cell adenocarcinoma.